
CLAIMS:

1. A solid form comprising Form I of Compound I:



(I),

which has an XRPD pattern comprising at least one peak selected from about 5.3, about 8.5, and about 18.0 °2θ, when measured using radiation with a wavelength of about 1.54 angstroms.

2. The solid form of claim 1, which has an XRPD pattern comprising at least two peaks selected from about 5.3, about 8.5, and about 18.0 °2θ, when measured using radiation with a wavelength of about 1.54 angstroms.

3. The solid form of claim 1 or 2, which has an XRPD pattern comprising peaks at about 5.3, about 8.5, and about 18.0 °2θ, when measured using radiation with a wavelength of about 1.54 angstroms.

4. The solid form of any one of claims 1-3, wherein the pattern further comprises peaks at about 16.3 and about 19.3 °2θ.

5. The solid form of any one of claims 1-4, wherein the pattern further comprises peaks at about 20.9 and about 21.4 °2θ.

6. The solid form of claim 1, which has an XRPD pattern comprising peaks at the following ten positions: about 5.3, about 8.5, about 10.6, about 15.5, about 16.3, about 18.0, about 18.4, about 19.3, about 20.9, about 21.4 °2θ, when measured using radiation with a wavelength of about 1.54 angstroms.

7. The solid form of claim 1, which has an XRPD pattern essentially as depicted in Figure 1.

8. The solid form of any one of claims 1-7, which has a DSC thermogram essentially as depicted in Figure 2.

9. The solid form of any one of claims 1-7, which has a DSC thermogram comprising an endotherm at about 133.5 °C.

10. The solid form of any one of claims 1-9, which has a TGA thermogram essentially as depicted in Figure 3.

11. The solid form of any one of claims 1-9, which has a TGA thermogram comprising a mass loss of less than about 1% between about 20°C and about 100°C.

12. The solid form of claim 11, wherein the mass loss is less than about 0.5%.

13. The solid form of claim 11 or 12, wherein the mass loss is about 0.25%.

14. The solid form of any one of claims 1-13, which is substantially crystalline.

15. The solid form of any one of claims 1-13, which is substantially pure.

16. The solid form of any one of claims 1-13, which is substantially crystalline and substantially pure.

17. A pharmaceutical composition comprising the solid form of any one of claims 1-16, in admixture with a pharmaceutically acceptable carrier or diluent.

18. The pharmaceutical composition of claim 17 for use as a medicament

19. The solid form of any one of claims 1-16 for use as a medicament.

20. Use of the solid form of any one of claims 1-16 in the manufacture of a medicament for the treatment of a disorder selected from schizophrenia, narcolepsy, excessive daytime sleepiness, obesity, attention deficit hyperactivity disorder, pain, Alzheimer's disease, cognition deficiency, Tourette's disorder, and cognition deficiency associated with schizophrenia.

21. Use of a pharmaceutical composition according to claim 17 in the manufacture of a medicament for the treatment of a disorder selected from schizophrenia, narcolepsy, excessive daytime sleepiness, obesity, attention deficit hyperactivity disorder, pain, Alzheimer's disease, cognition deficiency, Tourette's disorder, and cognition deficiency associated with schizophrenia.

22. The solid form of any one of claims 1-16 for use in the treatment of schizophrenia, narcolepsy, excessive daytime sleepiness, obesity, attention deficit hyperactivity disorder, pain, Alzheimer's disease, cognition deficiency, Tourette's disorder, or cognition deficiency associated with schizophrenia.

23. The pharmaceutical composition of claim 17 for use in the treatment of schizophrenia, narcolepsy, excessive daytime sleepiness, obesity, attention deficit hyperactivity disorder, pain, Alzheimer's disease, cognition deficiency, Tourette's disorder, or cognition deficiency associated with schizophrenia.


24. The use according to claim 20 or 21, wherein said pain is diabetic neuropathic pain.

25. The solid form according to claim 22, wherein said pain is diabetic neuropathic pain.

26. The pharmaceutical composition according to claim 23, said pain is diabetic neuropathic pain.

CLAIMS:

1. A solid form comprising Form I of Compound I:



(I),

which has an XRPD pattern comprising at least one peak selected from about 5.3, about 8.5, and about 18.0 °2θ, when measured using radiation with a wavelength of about 1.54 angstroms.

2. The solid form of claim 1, which has an XRPD pattern comprising at least two peaks selected from about 5.3, about 8.5, and about 18.0 °2θ, when measured using radiation with a wavelength of about 1.54 angstroms.

3. The solid form of claim 1 or 2, which has an XRPD pattern comprising peaks at about 5.3, about 8.5, and about 18.0 °2θ, when measured using radiation with a wavelength of about 1.54 angstroms.

4. The solid form of any one of claims 1-3, wherein the pattern further comprises peaks at about 16.3 and about 19.3 °2θ.

5. The solid form of any one of claims 1-4, wherein the pattern further comprises peaks at about 20.9 and about 21.4 °2θ.

6. The solid form of claim 1, which has an XRPD pattern comprising peaks at the following ten positions: about 5.3, about 8.5, about 10.6, about 15.5, about 16.3, about 18.0, about 18.4, about 19.3, about 20.9, about 21.4 °2θ, when measured using radiation with a wavelength of about 1.54 angstroms.

7. The solid form of any one of claims 1-6, which has a DSC thermogram comprising an endotherm at about 133.5 °C.

8. The solid form of any one of claims 1-7, which has a TGA thermogram comprising a mass loss of less than about 1% between about 20°C and about 100°C.

9. The solid form of claim 8, wherein the mass loss is less than about 0.5%.

10. The solid form of claim 8 or 9, wherein the mass loss is about 0.25%.

11. The solid form of any one of claims 1-10, which is substantially crystalline.

12. The solid form of any one of claims 1-10, which is substantially pure.

13. The solid form of any one of claims 1-10, which is substantially crystalline and substantially pure.

14. A pharmaceutical composition comprising the solid form of any one of claims 1-13, in admixture with a pharmaceutically acceptable carrier or diluent.

15. The pharmaceutical composition of claim 14 for use as a medicament.

16. The solid form of any one of claims 1-13 for use as a medicament.

17. The use of the solid form of any one of claims 1-13 for the preparation of a medicament for the treatment of a disease selected from schizophrenia, narcolepsy, excessive daytime sleepiness, obesity, attention deficit hyperactivity disorder, peripheral neuropathic pain or diabetic neuropathic pain, Alzheimer's disease, cognition deficiency, Tourette's disorder, and cognition deficiency associated with schizophrenia.

18. The use of the pharmaceutical composition according to claim 14 for the preparation of a medicament for the treatment of a disease selected from schizophrenia, narcolepsy, excessive daytime sleepiness, obesity, attention deficit hyperactivity disorder, peripheral

neuropathic pain or diabetic neuropathic pain, Alzheimer's disease, cognition deficiency, Tourette's disorder, and cognition deficiency associated with schizophrenia.

19. The solid form of any one of claims 1-13 for use in the treatment of schizophrenia, narcolepsy, excessive daytime sleepiness, obesity, attention deficit hyperactivity disorder, pain, Alzheimer's disease, cognition deficiency, Tourette's disorder, or cognition deficiency associated with schizophrenia.

20. The pharmaceutical composition of claim 14 for use in the treatment of schizophrenia, narcolepsy, excessive daytime sleepiness, obesity, attention deficit hyperactivity disorder, pain, Alzheimer's disease, cognition deficiency, Tourette's disorder, or cognition deficiency associated with schizophrenia.

21. The solid form according to claim 19, wherein said pain is peripheral neuropathic pain or diabetic neuropathic pain.

22. The pharmaceutical composition according to claim 20, wherein said pain is peripheral neuropathic pain or diabetic neuropathic pain.